Kendall Bowling, DO
Family Medicine · Hazard, KYNPI 1750535670
Payments from drug & device makers
Across 414 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Medtronic$1K
- GSK$690
- Boehringer Ingelheim$600
- Pfizer$587
- Novo Nordisk$565
- plus $3K from 34 others
Across 2 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$38
- Novo Nordisk$38
What the payments were for
- Travel & lodging$1,05913%
- Food & beverage$7,09187%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 72 | $1,772 |
| Medtronic | 10 | $1,306 |
| GSK | 52 | $690 |
| Boehringer Ingelheim | 45 | $600 |
| Pfizer | 40 | $587 |
| Novo Nordisk | 37 | $565 |
| AbbVie | 27 | $556 |
| Lilly USA, LLC | 24 | $351 |
| Amgen | 15 | $224 |
| Corcept Therapeutics | 11 | $221 |
| Sanofi-aventis U.S. LLC | 10 | $157 |
| Bayer | 9 | $149 |
| Merck | 11 | $148 |
| Johnson & Johnson | 7 | $115 |
| Gilead | 4 | $86 |
| Dexcom, Inc. | 4 | $86 |
| Amarin Pharma, Inc. | 5 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Exact Sciences | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Neurelis, Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Tonix Medicines, Inc. | 1 | $23 |
| Novartis | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Covis Pharma GmbH | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Grifols USA, LLC | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Metacel Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,185 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 288 | $259,859 |
| OzempicSemaglutide | 167 | $194,134 |
| JardianceEmpagliflozin | 188 | $180,912 |
| Tresiba Flextouch U-200Insulin Degludec | 95 | $88,999 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $87,541 |
| EliquisApixaban | 97 | $84,972 |
| RybelsusSemaglutide | 43 | $73,122 |
| LinzessLinaclotide | 74 | $58,586 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $58,186 |
| MounjaroTirzepatide | 49 | $54,963 |
| JanuviaSitagliptin Phosphate | 59 | $52,981 |
| TrulicityDulaglutide | 32 | $39,375 |
| Xigduo XrDapaglifloz Propaned/Metformin | 57 | $36,498 |
| XareltoRivaroxaban | 30 | $33,005 |
| VascepaIcosapent Ethyl | 63 | $30,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,772 | $318,045352 claims |
| Novo NordiskOzempic, Rybelsus | $565 | $267,256210 claims |
| Boehringer IngelheimJardiance, Tradjenta | $600 | $195,622212 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta | $690 | $115,572179 claims |
| Lilly USA, LLCMounjaro, Trulicity | $351 | $94,33881 claims |
| PfizerEliquis | $587 | $84,97297 claims |
| AbbVieLinzess | $556 | $58,58674 claims |
| MerckJanuvia | $148 | $52,98159 claims |
| Johnson & JohnsonXarelto | $115 | $33,00530 claims |
| NovartisEntresto | $21 | $24,65229 claims |
| BayerKerendia | $149 | $19,40519 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $5,79014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Hazard
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.